Trial Profile

A phase I study of vernakalant (Brinavess) in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Mar 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vernakalant (Primary)
Indications Atrial fibrillation
Focus Adverse reactions

Most Recent Events

10 Mar 2016 Status changed from planning to recruiting according to Cardiome Pharma media release.
29 Jul 2015 New trial record
24 Jul 2015 According to a Cardiome Pharma media release, this study will support the regulatory approval of vernakalant [BRINAVESS] in China. If BRINAVESS successfully completes Phase I, Eddingpharm anticipates initiating a pivotal Phase 3 study by year end.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com